Background. Risk prediction models allow for the incorporation of individualized risk and clinical effectiveness information to identify patients for whom therapy is most appropriate and cost-effective. This approach has the potential to identify inefficient (or harmful) care in subgroups at different risks, even when the overall results appear favorable. Here, we explore the value of personalized risk information and the factors that influence it. Methods. Using an expected value of individualized care (EVIC) framework, which monetizes the value of customizing care, we developed a general approach to calculate individualized incremental cost effectiveness ratios (ICERs) as a function of individual outcome risk. For a case study (tPA v. streptokinase to treat possible myocardial infarction), we used a simulation to explore how an EVIC is influenced by population outcome prevalence, model discrimination (c-statistic) and calibration, and willingness-to-pay (WTP) thresholds. Results. In our
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This study uses simulation to explore how the underlying characteristics of a decision scenario can influence the additional benefits to be derived from an individualized (risk-based) approach v. a ''one-size-fits-all'' approach, based on calculating the expected value of individualized care (EVIC). 6 In particular, we explore how changes in the clinical risk prediction model performance (such as predictive model discrimination and calibration) might influence the EVIC. At the same time, we assess the impact of different levels of willingness to pay and the average population risk. Our goal is to understand the decisional context for which an individualized, tailored, risk-based approach is most likely to add value, as well as when it might lead to harm.
THEORY Expected Value of Individualized Care
In this study, we use a previously developed framework of the EVIC, [6] [7] [8] the difference between the expected value of the best population-wide strategy-i.e., either treating every population member or treating no-one-and the expected value of selecting treatment for each population member individually.
Identifying and Valuing the Best Population-wide Strategy
By convention, we designate the expected value of treating no-one to be zero. The incremental value of treating everybody is therefore the monetized treatment benefit for the population (where benefits are monetized based on the ''willingness to pay'' (WTP) threshold) minus treatment costs, averaged over the entire population. If this incremental net benefit value is positive, treating everyone is the optimal population-wide strategy. Otherwise, treating no-one (value of zero) is the optimal populationwide strategy.
The analysis in this paper estimates each individual's treatment benefit by assuming it is proportional to the product of 3 quantities: 1) the baseline risk of the adverse event for an individual i in the absence of treatment, designated R i,baseline ; 2) the risk reduction conferred by treatment, designated 1 À RR tx ð Þ , where RR tx is the relative risk of the adverse event with treatment; and 3) the gain in quality of adjusted life years (QALY) associated with averting the adverse outcome, designated DQALY . Hence, the expected QALY gain from treatment of an individual i is R i,baseline 3 1À ð RR tx Þ3DQALY : Note that this formulation assumes that both RR tx and DQALY are the same for all members of the population; only baseline outcome risk (R i,baseline ) differs across individuals. This is a simplification that does not change the overall results of the framework presented. Each individual's outcome in the absence of treatment is not known ex ante but the baseline outcome risk can be estimated using a predictive model on the basis of the baseline characteristics of the individual.
Multiplying the expected QALY gain by WTP (the willingness to pay for one QALY) yields the expected monetized treatment benefit. If this benefit exceeds the treatment cost on average, then treating everyone is the optimal population-wide strategy, and its expected per-person value is WTP3
Here, R baseline is the average population baseline risk and Cost Tx is the per-patient treatment cost. Otherwise, the optimal population strategy is treating no-one and its monetized value is zero, by convention.
Valuing Individualized Care
We again estimate the benefits minus the costs for all members of the population. In this case, however, individuals receive treatment only if their monetized benefits exceed their costs. For individuals receiving treatment, the treatment value is WTP3R i,baseline 3 1 À RR tx ð Þ 3DQALY À Cost Tx , exactly as above; for others (who remain untreated), it is zero.
Assuming that the individualized decisions are based on accurate estimates, the EVIC cannot be negative; that is, individualized care must be at least as good as the best population-wide strategy, because it only eliminates treatments in those patients for whom treatment has a negative value. At worst, the EVIC is zero when the optimal decision does not vary across individuals and thus decision making is the same for both the individualized and ''one-size-fits-all'' approaches.
Perfect Risk Prediction
Consider a hypothetical clinical prediction model that perfectly predicts which population members will experience an adverse outcome in the absence of treatment. Under this condition, only the group that would benefit from treatment would receive it (assuming the therapy provides overall benefit to them, and they would not have a good outcome regardless of therapy).
If the optimal population-wide strategy is to treat everyone, then the EVIC is the difference between the value of targeting individuals who will experience an adverse outcome in the absence of treatment, and the value of treating everyone (including those who will not benefit from treatment or do well even if untreated). In the absence of treatment harm, the treatment benefit is the same for both strategies, because both strategies treat all members of the population who could benefit. The costs, however, differ. For the targeted strategy, the costs are N3 R baseline 3Cost Tx . For the ''treat all'' strategy, the costs are N3Cost Tx . The EVIC is the difference between these 2 values, or 1 À R baseline À Á N3Cost Tx and is maximized when R baseline is small, as a smaller number of patients would need to be treated with individualized care.
If the optimal population-wide strategy is ''treat none'' (value of zero by convention), then the EVIC is the treatment benefits minus the treatment costs. That is, the EVIC is N3
ÞÀCost Tx . Note that as R baseline increases, the EVIC also grows, because we would be changing the treatment strategy on a progressively higher number of individuals. This relationship may not be monotonic, because, at some value of R baseline , the optimal population strategy can switch between ''treat all'' and ''treat none''.
Imperfect Risk Prediction
We are interested in the EVIC in more typical circumstances in which the risk prediction is imperfect. Below, we consider briefly how the EVIC might change when model discrimination is imperfect and also when a model is miscalibrated.
Imperfect Discrimination
''Risk'' refers to the ex ante probability that a particular member of a population will ultimately experience an adverse outcome. Discrimination refers to the capacity of the model to assign higher risks to subjects who will ultimately experience the adverse outcome than to subjects who will not. Formally, discrimination is measured in terms of the c-statistic, which represents the proportion of all possible discordant subject pairs (i.e., pairs in which exactly one subject will experience the adverse outcome) that the model correctly orders by risk. That is, in a correctly ordered pair, the model predicts a higher risk for the subject who will experience the adverse outcome than it predicts for the subject who will not.
A model with perfect discrimination will always assign a higher risk to the subject who will experience the adverse outcome; so, such a model has a c-statistic value of 1.0 (100% of the pairs are correctly ordered). A model with no discriminatory power effectively ''flips a coin'' and hence has a 50% chance of correctly assigning a higher risk to the subject who will ultimately experience the adverse outcome. Therefore, a model with no discriminatory power has a c-statistic of 0.5 (50%). Note that the c-statistic says nothing about the relative magnitude of the risks assigned by the model to individuals who do and do not experience the adverse outcome; only the order matters. Figure 1 illustrates empirically derived risk distributions corresponding to c-statistic values ranging from 0.5 (model predictions are no better than chance) to 1.0 (model achieves perfect discrimination). At c-statistic values modestly exceeding 0.5 (e.g., c-statistic = 0.6), modeled risk estimates for population members cluster around the value of R baseline (risk values for some individuals are slightly above R baseline , whereas others are a bit below). That is, models with low c-statistic values typically predict that all subjects face similar risks, and these risks are roughly equal to the prevalence of the adverse outcome in the population. As the c-statistic increases, the resulting risk heterogeneity across the population increases because of improvements in the capacity of the model to discriminate high-from low-risk individuals. At c-statistic values closer to 1.0 (e.g., c-statistic = 0.8 or 0.9), the modelpredicted risk for a portion of the population is large (eventually approaching 1.0 as the c-statistic grows), whereas, for the remainder of the population, the model-predicted risk is small (approaching zero as the c-statistic grows); i.e., at high c-statistic values, the model distinguishes individuals very likely to experience the adverse outcome from those very likely not to.
In this paper, we use simulations to explore the relationship between the predictive model's c-statistic and the EVIC.
Imperfect Calibration
Calibration measures the extent to which modelpredicted prevalence approximates the actual outcome prevalence, typically across some subgrouping specification (e.g., risk deciles). When calibration is perfect, the model is unbiased, and treatment decisions made for each member of the population individually are at least as good as the population-wide optimal treatment, regardless of how good or poor the model discrimination. 9 Hence, in these circumstances, the EVIC is nonnegative.
Often, risk models do not accurately predict risk for individuals outside the population used to construct the model. They may overestimate risk across quantiles, underestimate risk across quantiles, be ''overfit'' (under-estimate in low risk and overestimate in high risk patients), be ''underfit'' (overestimate low risk, under-estimate high risk) or have various other patterns. The risk prediction model in these situations can be said to have poor ''external validity'', or be ''miscalibrated'' or ''biased''.
A miscalibrated model can incorrectly classify members of the population as to whether their expected benefit from treatment exceeds the treatment costs because the expected benefits are inaccurate. Misclassification can, in turn, produce erroneous treatment recommendations. Because the model recommendation might be erroneous, modelbased recommendations for individuals can be worse than the optimal population-wide treatment recommendation. As a result, for misclassified models, the EVIC can be negative.
Finally, miscalibration is a potential problem not just when risk models are used to individualize treatment decisions but anytime external evidence is applied to a population. Indeed, whenever applying clinical trial results to a population in actual practice, the degree of bias in the effect estimates is generally unknown, and thus population-wide recommendations can also yield sub-optimal population-wide decisions.
ILLUSTRATIVE CLINICAL EXAMPLE

Methods
We illustrate the concepts described above through a case study based on the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, a large, multicenter, randomized, clinical trial. The GUSTO trial showed that a newer, more expensive thrombolytic agent, tissue plasminogen activator (tPA), conferred a survival benefit compared with the contemporaneous standard agent, streptokinase, for the treatment of acute myocardial infarction (MI). 10 
Assumptions
We based the outcome rate and cost estimates for our simulations on the GUSTO trial. 10 We defined the adverse outcome event to be 30-day mortality. We assumed that the average population risk (R baseline ) for this outcome was 7%, that tPA achieves a 15% relative-risk reduction (RR Tx 50:85) for mortality as compared with streptokinase, and that the total cost difference for patients treated with tPA v. streptokinase (Cost Tx ) was $2,000. This difference incorporates the short-term, direct medical costs. We assumed that the QALY gain from averting death at 30 days is 12 additional QALYs, an estimate corresponding to average survival duration for acute MI survivors, [11] [12] [13] but that there is no additional difference in QALYs due to treatment choice. Further, to simplify interpretation, we excluded future health care costs for MI survivors beyond the costs of the tPA and streptokinase treatment. We investigated the impact of altering some of these assumptions, using the ranges detailed in Table 1 .
Identifying the Optimal Population-wide Strategy
In addition to the effectiveness and cost of a treatment, the optimal population-wide strategy (''treat all'' or ''treat none'') depended on several factors. These factors were the expected prevalence of the adverse outcome (in this example, the 30 day mortality rate R baseline ), and the monetized value of each QALY gained (i.e., the decision maker's WTP threshold). Specifically, Net Benefit = WTP3 R baseline 3 1 À RR tx ð Þ 3DQALY À Cost Tx . If R Baseline 50, treatment can have no benefit, and net benefits cannot exceed zero (if treatment incurs any cost, net benefits will be negative). As R Baseline increases, the net benefits increase with a slope of WTP3 1À ð RR tx Þ3DQALY (see Figure 1 ). For R baseline 5
Cost Tx WTP3 1ÀRR Tx ð Þ 3DQALY , net benefit is zero.
Generating Baseline Risk Values for Each Simulated Population Member
We assigned to each member of our simulated population a baseline risk value drawn from a beta probability distribution. We created a series of baseline risk probability distributions, each corresponding to assumed values for 1) the population adverse event prevalence (R Baseline 55%,7%,10%, or 20%), and 2) the c-statistic, with values ranging from 0.5 (no discriminatory power, to 0.9 (high discriminatory power).
In summary, a different risk distribution corresponds to each combination of values for R baseline and the c-statistic, and can be modeled for a given population and predictive model, as previously shown in an analysis of 32 large clinical trials by Kent and others. 14 We described each distribution as a beta distribution with parameters that depend on the assumed values for the c-statistic and population prevalence, R baseline , in our simulations. We estimated the beta distribution parameters from empirical relationships across multiple clinical trials, derived previously. 14 To characterize the beta distribution, we first estimated the alpha parameter using ordinary least squares regression applied to alpha values derived for specific beta distributions fitted to each clinical trial in a set of 25 large, randomized clinical trials (including ACCORD, 15 AFFIRM, 16 ALLHAT, 17, 18 AMIS, 19 BARI, 20 BEST, 21 BHAT, 22 CAST, 23 CPPT, 24 DCCT, 25 DIG, 26 DPP, 27 ENRICHD, 28 , FAVORIT, 29 HALTC, 30 HDFP, 31 HEMO, 32 MRFIT, 33 MTOPS, 34 OAT, 35 PEACE, 36 ROC, 37, 38 SHEP, 39 SOLVD, 40, 41 and TIMI II. 42 ) The resulting relationship was lna59:35 À 12:15c, where c is the c-statistic. The R 2 for this regression was 0.90. After estimating a, we estimated b from the relationship a a1b 5p, where p is the population prevalence of the adverse outcome (equal to R baseline ). Because the clinical trials in our sample had c-statistic values ranging from 0.58 to 0.75, our characterization of the population baseline risk distribution was least uncertain in this range.
We simulated a cohort of 5,000 individuals for each scenario (i.e., for each combination of c-statistic and R baseline values). For each scenario, we reported the EVIC and the population distribution of cost-effectiveness ratios. By comparing scenarios, we described how the cost-effectiveness distribution changes in response to changes in the assumed discriminatory power of the risk model.
EVIC when Risk Estimates Are Well Calibrated
To calculate EVIC, we first identified the optimal ''one-size-fits-all'' population strategy (treat all or treat none) for each scenario. We then identified the optimal strategy for each population member based on his or her baseline 30-day mortality risk. Specifically, we identified tPA to be the optimal treatment for an individual i if WTP3 R i,baseline 3 1 À RR tx ð Þ 3DQALY .Cost Tx , where R i,baseline is the baseline 30-day mortality risk for that individual, 1 À RR tx ð
Þis the relative risk conferred by tPA, and Cost Tx is the incremental cost of tPA compared with streptokinase treatment. Finally, we estimated EVIC by summing the monetized gains accrued for all population members for whom the individualized treatment differed from the optimal populationwide strategy, and averaging them across the population. For example, if the optimal population-wide strategy was ''treat none'', the EVIC was the sum of the monetized net gains accrued for all population members who, based on an individualized care, switched to treatment.
EVIC when Risk Estimates Are Miscalibrated
For this scenario, we first characterized the ''true'' baseline risk distribution using the approach described above for the perfect calibration scenario. We then calculated a reported baseline risk value for each member of the simulated cohort-the value that would be observed in the ''real world''-by multiplying that individual's simulated ''true'' baseline risk value by a miscalibration factor that ranged from 0.5 (underestimate) to 2.0 (overestimate). Next, we identified a putative optimal treatment for each individual by plugging that individual's reported baseline risk value into the benefit expression (WTP3 R i,baseline 3 1 À RR tx ð Þ 3DQALY ) and comparing it to tPA's incremental cost. The EVIC was calculated based on the ''true'' underlying costs and benefits of the selected treatment for each individual.
Results
Mortality
Risk and Cost-effectiveness of Population-wide Treatment Figure 2 illustrates the relationship between the net benefit of treating all patients with MI with tPA (vertical axis) when assumptions about the 30-day mortality (horizontal axis) are varied. As expected, the net benefit is negative when the 30-day mortality is low and the net benefit is greatest when the 30-day mortality is highest. As illustrated in Figure  2 , if a QALY is worth $100,000, the net benefits are zero when the population 30-day mortality is assumed to be 1.1% (i.e., P 100k 51:1%). The corresponding break-even points for QALY values of $50,000 and $100,000 are P 50k 52:2%, and P 20k 55:6%, respectively. When the populationwide mortality risk falls below these thresholds, the optimal population-wide strategy is to treat none (i.e., use streptokinase in all patients); when the average mortality risk is higher, the optimal population-wide strategy is to treat all.
For example, if the QALY value (WTP) = $50,000/QALY, the EVIC for a model with a c-statistic of 0.8 is $200 per population member when R baseline = 20%. The per-person EVIC of the same model increases to $500 in a population with a R baseline 55%, because R baseline 55% is closer to the break-even risk value of 2% (Figure 2) . Similarly, when WTP = $20,000/QALY, the break-even average 30-day mortality is approximately 6%, and the EVIC is in fact highest when R baseline is between 5% and 7%.
Holding R baseline constant and, instead, changing the assumed monetized value of a QALY (WTP) likewise influences the EVIC for analogous reasons. As the WTP becomes smaller (e.g., reducing it from $100,000/QALY to $20,000/QALY), the EVIC increases from $350 per subject to $700 per subject. Note that, in both scenarios, the optimal population-wide strategy is to treat all with tPA. But, as the value for WTP falls, the less-expensive streptokinase therapy becomes the optimal strategy for a growing number of population members, because individualized care accrues benefits for this growing number of individuals (by switching these patients from tPA to streptokinase) so that the EVIC increases. Figure 3 illustrates the individualized costeffectiveness value distributions corresponding to different assumptions regarding the risk model's discriminatory power. Because a well-calibrated model with low discriminatory power (c-statistic) yields similar baseline risks for all members of the population, individualized cost-effectiveness estimates are likewise similar for all members of the population, and the mean and median cost-effectiveness estimates do not substantially differ. As discriminatory power improves, the predicted risk varies across population members and so do the individualized ICERs. The individualized costeffectiveness of tPA for some patients (i.e., those at low risk for mortality) becomes highly unfavorable (very large) as the incremental benefit in the costeffectiveness ratio denominator becomes small; for others (i.e., those at high risk), tPA's cost-effectiveness ratio becomes more favorable (relatively small) as the incremental benefit in the ratio's denominator grows. Because the resulting distribution of the cost-effectiveness ratios is skewed, the mean and median diverge, making tPA less worthwhile in the typical patient.
Changes in Individualized ICER with Changes in Discrimination
EVIC when Risk Estimates Are Perfectly Calibrated Figure 4 illustrates our EVIC calculations for the simulated cohorts. The EVIC ranges from $0 to $700 per person, with better discrimination (higher c-statistic values) yielding higher EVIC values. The association between the discriminatory power and the EVIC persists across different assumed values for baseline, average 30-day mortality (R baseline ) and the monetized value for a QALY (WTP). Figure 5 illustrates our findings for scenarios in which the prediction models produce miscalibrated individual risk estimates. Under the assumptions in our study, the EVIC ranged from 2$600 to $700 per person, reflecting a lower value for individualized care as compared with the optimal population-wide decisions in some circumstances. The most striking feature of these results is evident in the plots on the left ( Figure 5 ; miscalibration factor of 0.5, meaning that the model-reported risk underestimates each individual, true 30-day mortality probability by one-half). In those plots, improvements in discrimination were nonmonotonically related to changes in the EVIC. Increasing the discriminatory power lowered the EVIC when discrimination was low (i.e., as the c-statistic improved from 0.5 to between 0.6 and 0.7) but then increased the EVIC when the c-statistic was higher (i.e., as the c-statistic improves to between 0.8 and 0.9).
EVIC when Risk Estimates Are Miscalibrated
DISCUSSION
Cost-effectiveness analyses are typically performed at a population level, yet most medical decisions are made, and most resources are allocated, one patient at a time. Therefore, cost-effectiveness analyses are generally at a level that is incongruent with medical decision making, and individual costeffectiveness estimates can vary substantially from the overall average cost-effectiveness. 13, 43, 44 In the simulations reported, we examined the value of individualizing information based on estimates of individual patient risk. Our results suggest that individualizing treatment decisions may yield substantial value, but also has the potential for harm. We have verified what others have observed for well-calibrated models: the EVIC increases as discriminatory power increases. 9 As model discrimination improves, the risk heterogeneity increases, and, consequently, there is also greater heterogeneity in individual ICER estimates. Because these individual ICER estimates may diverge substantially from the population average (and the ICER for the typical patient may be quite different from the population average), the optimized individualized strategy may diverge substantially from the optimized strategy based on a population average. Our simulations, based on a simplified version of a classic cost-effectiveness analysis, suggest that moderate improvements in discrimination can add substantial value, equivalent to several hundred dollars on a per person basis in some scenarios.
When models are well calibrated, individualized risk based decisions are, at worst, non-harmful. This is consistent with the findings in other work using a decision analytic framework. 9 We also found that well-calibrated risk models are of greatest value to decisions when the overall prevalence places a population-wide strategy near the decision threshold and when model discrimination is good. When the mortality risk yields an incremental cost-effectiveness ratio that is far from the WTP decision threshold, the optimal population-wide and individualized strategies will be the same and the EVIC will be near-zero, except when model discrimination is very good.
The EVIC is higher when the population baseline risk estimate ( R baseline ) is closer to the ''break-even'' value that makes the expected net benefit or incremental monetized value of tPA close to zero. In this circumstance, there is no clear advantage to either the ''treat all with tPA'' or ''treat none with tPA'' strategy (see Figure 1 ). This balance implies that the break-even risk value is nearer to the middle of the population risk distribution, and that the optimized individualized strategy will differ from the best population-wide option (either treat all with tPA or treat none with tPA) for many. Hence, individualized care will result in a substantial number of treatment switches, and because gains from individualized care accrue only in these switched cases, the EVIC can grow larger as discrimination improves and the risk distribution broadens.
Our analysis goes beyond past work by carefully examining what happens when models are miscalibrated. That scenario is important, because, in the real world, models are typically developed on one population and applied to others. When models are miscalibrated, the EVIC can be negative and improvements in model discrimination can paradoxically decrease the value of individualizing care in some circumstances. We explored the impact of individualization based on miscalibrated predictive models, which can lead to treatment assignment ''mistakes''. When the population average ICER is near the WTP threshold, decision making is more sensitive to miscalibration and these treatment assignment mistakes are more common (making the EVIC more negative). This can be explained by looking at the distribution of individual ICERs (Figure 3) . The effect of model miscalibration in our simulation was to shift the ICERs of some individuals across the WTP threshold, leading to the wrong decision for those patients, thus lowering the overall EVIC. When the WTP threshold is not close to the population ICER, the change in individual ICERs does not affect the treatment decision, and there is no effect on the overall EVIC. Interestingly, a poor c-statistic can sometimes protect from misclassification due to bias, which becomes revealed only when the c-statistic improves; thus, greater discriminating power can paradoxically reduce the EVIC under some circumstances.
These simulations were based on several simplifying assumptions. Most importantly, we assumed the following parameters were independent of baseline risk: treatment effect (measured as relative risk reduction); treatment costs; and QALYs gained conditioned on outcome. It is likely that long-term costs and life expectancy or QALYs are correlated with the short-term outcome risk. For example, individuals at higher risk of a cardiovascular death are also more likely to be older and have more severe heart attacks and other risk factors or health conditions that would impact their long-term life expectancy. Including the correlations between short-term risk and long-term benefit in the decision model is likely to attenuate the heterogeneity of individualized benefits across the population (and diminish the EVIC); although, it may be difficult to generalize whether this would be true across other conditions. A further complicating factor not included in this analysis is the heterogeneity of treatment-related harm (i.e., intracranial bleeding), 12 especially its interplay with the heterogeneity of the individual outcome risk and benefit from treatment. These issues underscore the heavy data and analytical burden of more individualized cost-effectiveness studies.
Individualized estimates can help determine the treatment course. However, predictive models should be used with care and an understanding of the applicability of the model. First, if the treatment's average cost-effectiveness is far from any important decision threshold, there is a high probability that the optimal population-wide strategy is the right course for any individual. When the net benefit of a population-wide strategy is near zero, individualized information may be very helpful in assigning the best treatment strategy. Second, if a predictive model has poor discriminating power, it may be of very low value. Finally, poorly calibrated models may provide misleading predictions and cause patient harm, reducing the EVIC. These results emphasize the importance of paying special attention to the decisional context in which models will be deployed and to model calibration, an often neglected aspect of predictive model validation. Caution is needed when transporting risk models to new settings. In general, models developed on local samples are anticipated to be better calibrated than models developed on ''different but related'' samples. Whenever possible, risk models should be updated and recalibrated to ensure the accuracy of the risk information they yield. While the potential for miscalibration is ubiquitous, more research is needed to determine those situations in which risk models are especially likely to be vulnerable to miscalibration.
